Unknown

Dataset Information

0

HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants.


ABSTRACT: Integrase strand transfer inhibitors (INSTIs) block the integration step of the retroviral lifecycle and are first-line drugs used for the treatment of HIV-1/AIDS. INSTIs have a polycyclic core with heteroatom triads, chelate the metal ions at the active site, and have a halobenzyl group that interacts with viral DNA attached to the core by a flexible linker. The most broadly effective INSTIs inhibit both wild-type (WT) integrase (IN) and a variety of well-known mutants. However, because there are mutations that reduce the potency of all of the available INSTIs, new and better compounds are needed. Models based on recent structures of HIV-1 and red-capped mangabey SIV INs suggest modifications in the INSTI structures that could enhance interactions with the 3'-terminal adenosine of the viral DNA, which could improve performance against INSTI resistant mutants. We designed and tested a series of INSTIs having modifications to their naphthyridine scaffold. One of the new compounds retained good potency against an expanded panel of HIV-1 IN mutants that we tested. Our results suggest the possibility of designing inhibitors that combine the best features of the existing compounds, which could provide additional efficacy against known HIV-1 IN mutants.

SUBMITTER: Smith SJ 

PROVIDER: S-EPMC8205226 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7449158 | biostudies-literature
| S-EPMC6125528 | biostudies-literature
| S-EPMC5956922 | biostudies-literature
| S-EPMC3983366 | biostudies-other
| S-EPMC2660605 | biostudies-literature
| S-EPMC4836387 | biostudies-literature
| S-EPMC6496081 | biostudies-literature
| S-EPMC4674865 | biostudies-literature
| S-EPMC4216207 | biostudies-other
| S-EPMC2866738 | biostudies-literature